glaxosmithkline pharmaceutical (citi) Inline 1Q; DPCO Provision Hits Reported PAT

Inline, steady; Steady revenue growth; EBITDA margin lower, PAT beats expectations; Provisions for DPCO-related demand pulls down reported PAT
Date Rating Target Price Recommendation Price Broker house
8 May 2011 sell 2100 2287 citi Report

No comments:

Post a Comment